Arrowstreet Capital, Limited Partnership and Arrowstreet Capital Holding LLC filed a Schedule 13G Amendment No. 1 with the SEC on November 13, 2026, disclosing a beneficial ownership position in Lovesac Co common shares as of September 30, 2026.
Karpus Management, Inc. filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 1,723,675 shares of common stock in JAB Acquisition Corp I, representing 6.06% of the class, as of September 30, 2026.
CapitalG filed an amended Schedule 13G on November 13, 2026, disclosing beneficial ownership positions in Freshworks Inc. as of September 30, 2026, through multiple related Delaware entities.
Arrowstreet Capital, Limited Partnership and Arrowstreet Capital Holding LLC filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 17,344,813 common shares of Freshworks Inc. as of September 30, 2026.
Karpus Management, Inc. filed an amended Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of preferred shares of Carlyle Credit Income Fund as of September 30, 2026.
Karpus Management, Inc. filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 3,300,023 shares of common stock in Drugs Made In America Acquisition II Corp., representing 5.18% of the class as of September 30, 2026.
Amesite Inc. filed a Form 8-K on November 13, 2026, disclosing that it received a deficiency notification from Nasdaq on November 11, 2026, for failing to maintain the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
Oklo Inc. officer Vivek Narayanadas submitted a Form 144 notice of proposed sale on November 13, 2026, indicating an intent to sell 936 Class A shares with an aggregate market value of $22,055.25 through Fidelity Brokerage Services LLC on the NYSE.
Tonix Pharmaceuticals Holding Corp. filed a complaint for patent infringement against Dr. Reddy's Laboratories in the U.S. District Court for the District of New Jersey on November 13, 2026, following Dr. Reddy's submission of an ANDA for a generic version of TONMYA.
aTyr Pharma, Inc. filed a Form 8-K on November 13, 2026, disclosing that Nasdaq notified the company it had regained compliance with the minimum closing bid price requirement after its common stock closed at $1.00 per share or greater for 10 consecutive business days.